EVUSHELD COVID-19 MONOCLONAL ANTIBODY UPDATE

1.27.2023

Situation/Background

As of January 26th, 2023, the FDA has withdrawn Emergency Use Authorization (EUA) for tixagevimab/cilgavimab (EVUSHELD®) secondary to reduced susceptibility to currently circulating COVID-19 variants.

HHS has suspended allocation and distribution of tixagevimab/cilgavimab (EVUSHELD®)

Assessment

The Osborn NSI infusion clinic has been previously providing EVUSHELD®) secondary to referral for patients meeting criteria for pre-exposure prophylaxis.

Recommendation

While HonorHealth recognizes that some patients may benefit from this therapy option, given the l impending risk of treatment ineffectiveness, tixagevimab/cilgavimab (EVUSHELD®) will no longer be offered as a treatment option within HonorHealth .